HomeCompareZLIOY vs JNJ

ZLIOY vs JNJ: Dividend Comparison 2026

ZLIOY yields 4.38% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZLIOY wins by $2.73M in total portfolio value
10 years
ZLIOY
ZLIOY
● Live price
4.38%
Share price
$11.50
Annual div
$0.50
5Y div CAGR
61.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.76M
Annual income
$2,024,164.35
Full ZLIOY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ZLIOY vs JNJ

📍 ZLIOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZLIOYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZLIOY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZLIOY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZLIOY
Annual income on $10K today (after 15% tax)
$372.03/yr
After 10yr DRIP, annual income (after tax)
$1,720,539.70/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ZLIOY beats the other by $1,716,553.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZLIOY + JNJ for your $10,000?

ZLIOY: 50%JNJ: 50%
100% JNJ50/50100% ZLIOY
Portfolio after 10yr
$1.40M
Annual income
$1,014,426.88/yr
Blended yield
72.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ZLIOY
No analyst data
Altman Z
1.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZLIOY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZLIOYJNJ
Forward yield4.38%2.13%
Annual dividend / share$0.50$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR61.8%28%
Portfolio after 10y$2.76M$30.3K
Annual income after 10y$2,024,164.35$4,689.40
Total dividends collected$2.67M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZLIOY vs JNJ ($10,000, DRIP)

YearZLIOY PortfolioZLIOY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,408$708.18$10,592$272.30+$816.00ZLIOY
2$13,428$1,221.67$11,289$357.73+$2.1KZLIOY
3$16,543$2,174.49$12,123$472.89+$4.4KZLIOY
4$21,752$4,050.77$13,141$629.86+$8.6KZLIOY
5$31,328$8,054.04$14,408$846.81+$16.9KZLIOY
6$51,062$17,540.94$16,021$1,151.60+$35.0KZLIOY
7$97,869$43,232.51$18,122$1,588.22+$79.7KZLIOY
8$230,020$125,299.97$20,930$2,228.20+$209.1KZLIOY
9$691,434$445,313.11$24,792$3,191.91+$666.6KZLIOY
10$2,763,999$2,024,164.35$30,274$4,689.40+$2.73MZLIOY

ZLIOY vs JNJ: Complete Analysis 2026

ZLIOYStock

Zoomlion Heavy Industry Science and Technology Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of construction and agricultural machinery in the People's Republic of China and internationally. The company operates through three segments: Construction Machinery, Agricultural Machinery, and Financial Services. It offers concrete machineries, including truck-mounted concrete pumps, trailer-mounted concrete pumps, dry mortar products, concrete placing booms, concrete mixing plants, truck-mounted concrete mixers, truck-mounted line concrete pumps, and self-propelled boom concrete pumps; and cranes, such as truck cranes, all-terrain truck cranes, crawler cranes, and various types of tower cranes. The company also provides road construction and pile foundation machinery, earth working machinery, material handling machineries and systems, specialized vehicles, and vehicle axles; road building and maintenance machinery; hoisting machinery; and forklift trucks and other products for infrastructure and real estate construction. In addition, it offers various agricultural machineries comprising tractors, grain harvesters, and drying machines. Further, the company provides finance leasing, commercial factoring, and bond issuance services. Additionally, it leases and trades in equipment and machineries; researches and manufactures machine software, motor vehicle components, and hydraulic products; and exploits and manages tourism resources. The company was formerly known as Changsha Zoomlion Heavy Industry Science and Technology Development Co., Ltd. and changed its name to Zoomlion Heavy Industry Science and Technology Co., Ltd. in October 2011. Zoomlion Heavy Industry Science and Technology Co., Ltd. was founded in 1992 and is based in Changsha, the People's Republic of China.

Full ZLIOY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ZLIOY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZLIOY vs SCHDZLIOY vs JEPIZLIOY vs OZLIOY vs KOZLIOY vs MAINZLIOY vs ABBVZLIOY vs MRKZLIOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.